Evidence map›Paper›PMID 34997473›Full record

ArticleJournal of neurovirology2022

Longitudinal, virological, and serological assessment of hospitalized COVID-19 patients.

Lucia Signorini, Maria Dolci, Nicolò Castelnuovo, Luigia Crespi, Barbara Incorvaia, Pietro Bagnoli, Silvia Parapini, Nicoletta Basilico, Cristina Galli, Federico Ambrogi and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurovirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Lucia SignoriniDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy.
Maria DolciDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy.
Nicolò CastelnuovoIstituto Clinico Città Studi (ICCS), Via Jommelli 17, 20133, Milan, Italy.
Luigia CrespiIstituto Clinico Città Studi (ICCS), Via Jommelli 17, 20133, Milan, Italy.
Barbara IncorvaiaIstituto Clinico Città Studi (ICCS), Via Jommelli 17, 20133, Milan, Italy.
Pietro BagnoliIstituto Clinico Città Studi (ICCS), Via Jommelli 17, 20133, Milan, Italy.
Silvia ParapiniDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Nicoletta BasilicoDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy.
Cristina GalliDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Federico AmbrogiDepartment of Clinical and Community Sciences, University of Milan, Milan, Italy.
Elena ParianiDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Sandro BindaDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Rosalia TicozziDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy.
Pasquale FerranteDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy. Pasquale.ferrante@unimi.it.ORCID 0000-0001-7040-7293
Serena DelbueDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy.
University of Milan · ITIstituto di Sessuologia Clinica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we described the virological and serological assessment of 23 COVID-19 patients hospitalized and followed up in Milan, Italy, during the first wave of COVID-19 pandemic. Nasopharyngeal (NPS), anal swabs, and blood samples were collected from 23 COVID-19 patients, at hospital admission, and periodically up to discharge, for a median time of 20 days (3-83 days). RNA was isolated and tested for SARS-CoV-2 by qRT-PCR; anti-SARS-CoV-2 IgM and IgG antibody titers were evaluated in serum samples by ELISA. SARS-CoV-2 genome was detected in the NPS swabs of the 23 patients, at the admission, and 8/19 (42.1%) were still positive at the discharge. Anal swabs were positive to SARS-CoV-2 RNA detection in 20/23 (86.9%) patients; 6/19 (31.6%) were still positive at discharge. The mean time of RNA negative conversion was 17 days (4-36 days) and 33 days (4-77 days), for NPS and anal swabs, respectively. SARS-CoV-2-RNA was detected in the blood of 6/23 (26.1%) patients. Thirteen/23 (56.5%) and 17/23 (73.9%) patients were seropositive for IgM and IgG, respectively, at the admission, and the median IgM and IgG levels significantly (p < 0.05) increased after 13 days. Although the limited cohort size, our report provides evidence that SARS-CoV-2 is shed through multiple routes, with important implications in healthcare settings.

Indexed as

COVID-19Antibodies, ViralHumansImmunoglobulin GImmunoglobulin MPandemicsRNA, ViralSARS-CoV-2Antibodies, ViralImmunoglobulin GImmunoglobulin MRNA, ViralAnal swabsAnti-SARS-CoV-2 antibodiesBloodNasopharyngeal swabsSARS-CoV-2

Identifiers

PMID34997473
PMCPMC8740865
OpenAlexW4206483413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.